BACKGROUND: The Beck Depression Inventory, 2nd edition (BDI-II) is widely used in research on @entity308 . However, the @entity922 ( @entity922 ) is unknown. @entity922 can be estimated in several ways. Here we take a @entity1 -centred approach, anchoring the change on the BDI-II to the @entity1 's global report of improvement. METHOD: We used data collected (n  =  1039) from three randomized controlled trials for the management of @entity308 . Improvement on a 'global rating of change' question was compared with changes in BDI-II scores using general linear modelling to explore baseline dependency, assessing whether @entity922 is best measured in absolute terms (i.e. difference) or as percent reduction in scores from baseline (i.e. ratio), and receiver operator characteristics (ROC) to estimate @entity922 according to the optimal threshold above which individuals report feeling 'better'. RESULTS: Improvement in BDI-II scores associated with reporting feeling 'better' depended on initial @entity308 severity, and statistical modelling indicated that @entity922 is best measured on a ratio scale as a percentage reduction of score. We estimated a @entity922 of a 17.5% reduction in scores from baseline from ROC analyses. The corresponding estimate for individuals with longer duration @entity308 who had not responded to antidepressants was higher at 32%. CONCLUSIONS: @entity922 on the BDI-II is dependent on baseline severity, is best measured on a ratio scale, and the @entity922 for treatment-resistant @entity308 is larger than that for more typical @entity308 . This has important implications for clinical trials and practice.

Minimal clinically important difference on the Beck Depression Inventory - II according to the XXXX 's perspective.

@entity1 :: ('9606', 'Species') :: ['patient'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depression'] @entity922 :: ('MESH:D013568', 'Disease') :: ['minimal clinically important difference', 'MCID']
@entity1 :: (9606,Species) :: ['patient']
